Abstract:Summary Background Broad-capture proteomic technologies have the potential to improve disease prediction, enabling targeted prevention and management, but studies have so far been limited to very few selected diseases and have not evaluated predictive performance across multiple conditions. We aimed to evaluate the potential of serum proteins to improve risk prediction over and above health-derived information and polygenic risk scores across a diverse set of 24 outcomes. Methods We designed multiple case-cohorts nested in the EPIC-Norfolk prospective study, from participants with available serum samples and genome-wide genotype data, with more than 32 974 person-years of follow-up. Participants were middle-aged individuals (aged 40–79 years at baseline) of European ancestry who were recruited from the general population of Norfolk, England, between March, 1993 and December, 1997. We selected participants who developed one of ten less common diseases within 10 years of follow-up; we also subsampled a randomly drawn control subcohort, which also served to investigate 14 more common outcomes (n>70), including all-cause premature mortality (death before the age of 75 years; case numbers 71–437; controls 608–1556). Individuals were excluded from the current study owing to failed genotyping or proteomic quality control, relatedness, or missing information on age, sex, BMI, or smoking status. We used a machine learning framework to derive sparse predictive protein models for the onset of the the 23 individual diseases and all-cause premature mortality, and to derive a single common sparse multimorbidity signature that was predictive across multiple diseases from 2923 serum proteins. Findings Participants who developed one of ten less common diseases within 10 years of follow-up included 482 women and 507 men, with a mean age at baseline of 64·56 years (8·08). The random subcohort included 990 women and 769 men, with a mean age of 58·79 years (9·31). As few as five proteins alone outperformed polygenic risk scores for 17 of 23 outcomes (median dfference in concordance index [C-index] 0·13 [0·10–0·17]) and improved predictive performance when added over basic patient-derived information models for seven outcomes, achieving a median C-index of 0·82 (IQR 0·77–0·82). This included diseases with poor prognosis such as lung cancer (C-index 0·85 [+/− cross-validation error 0·83–0·87]), for which we identified unreported biomarkers such as C-X-C motif chemokine ligand 17. A sparse multimorbidity signature of ten proteins improved prediction across seven outcomes over patient-derived information models, achieving performances (median C-index 0·81 [IQR 0·80–0·82]) similar to those of disease-specific signatures. Interpretation We show the value of broad-capture proteomic biomarker discovery studies across multiple diseases of diverse causes, pointing to those that might benefit the most from proteomic approaches, and the potential to derive common sparse biomarker panels for prediction of multiple diseases at once. This framework could enable follow-up studies to explore the generalisability of proteomic models and to benchmark these against clinical assays, which are required to understand the translational potential of these findings. Funding Medical Research Council, Health Data Research UK, UK Research and Innovation–National Institute for Health and Care Research, Cancer Research UK, and Wellcome Trust.

Population Serum Proteomics Uncovers a Prognostic Protein Classifier for Metabolic Syndrome.

Plasma Metabolic Fingerprints for Large-Scale Screening and Personalized Risk Stratification of Metabolic Syndrome

Multi-stage metabolomics and genetic analyses identified metabolite biomarkers of metabolic syndrome and their genetic determinants

Serum betatrophin level increased in subjects with metabolic syndrome: a case-control study

A Non-invasive Model for Detection of Undiagnosed Metabolic Syndrome in School Children and Adolescents

Discovery of Metabolite Profiles of Metabolic Syndrome Using Untargeted and Targeted LC–MS Based Lipidomics Approach

Predictive Modeling the Probability of Suffering from Metabolic Syndrome Using Machine Learning: A Population-Based Study

External Validation of the Prognostic Prediction Model for 4-Year Risk of Metabolic Syndrome in Adults: A Retrospective Cohort Study

Reporting and Methods in Developing Prognostic Prediction Models for Metabolic Syndrome: A Systematic Review and Critical Appraisal.

Plasma Signature Metabolites of Dietary Fat Intake Characterize Associations with Prevalent Metabolic Syndrome

[Risk prediction of metabolic syndrome and coronary artery disease in overweight and obese populations based on serum metabolomics]

Proteome-wide Assessment of 10,000 Plasma Proteins with Age-Related Diseases and Multi-Morbidity in a Chinese Population

Identification of Novel Biomarkers for Metabolic Syndrome Based on Machine Learning Algorithms and Integrated Bioinformatics Analysis

Plasma Proteomic Profiles Predict Individual Future Health Risk.

Serum metabolomics profiling of improved metabolic syndrome is characterized by decreased pro-inflammatory biomarkers: a longitudinal study in Chinese male adults

Machine learning of plasma metabolome identifies biomarker panels for metabolic syndrome: findings from the China Suboptimal Health Cohort

Precise diagnosis and risk stratification of prostate cancer by comprehensive serum metabolic fingerprints: A prediction model study

How to Screen and Prevent Metabolic Syndrome in Patients of PCOS Early: Implications From Metabolomics

Machine Learning Identification of Nutrient Intake Variations across Age Groups in Metabolic Syndrome and Healthy Populations

Proteomic prediction of diverse incident diseases: a machine learning-guided biomarker discovery study using data from a prospective cohort study

Circulating Proteome and Progression of Type 2 Diabetes